PDS Planning’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.31M Sell
6,926
-44
-0.6% -$8.28K 0.08% 126
2026
Q1
$1.37M Buy
6,970
+1,044
+18% +$201K 0.09% 105
2025
Q4
$1.09M Buy
5,926
+90
+2% +$15.8K 0.07% 130
2025
Q3
$895K Buy
5,836
+589
+11% +$89.1K 0.06% 145
2025
Q2
$733K Sell
5,247
-121
-2% -$17K 0.05% 170
2025
Q1
$789K Buy
5,368
+781
+17% +$113K 0.07% 139
2024
Q4
$601K Sell
4,587
-81
-2% -$11.3K 0.05% 163
2024
Q3
$727K Sell
4,668
-1,024
-18% -$165K 0.07% 134
2024
Q2
$888K Buy
5,692
+357
+7% +$53.7K 0.09% 96
2024
Q1
$723K Buy
5,335
+140
+3% +$18.5K 0.08% 114
2023
Q4
$700K Sell
5,195
-181
-3% -$23.5K 0.08% 103
2023
Q3
$728K Buy
5,376
+173
+3% +$23.6K 0.09% 94
2023
Q2
$745K Buy
5,203
+164
+3% +$24.1K 0.1% 95
2023
Q1
$700K Buy
5,039
+1,346
+36% +$181K 0.1% 93
2022
Q4
$501K Buy
3,693
+35
+1% +$4.39K 0.08% 95
2022
Q3
$401K Sell
3,658
-25
-0.7% -$3.17K 0.07% 100
2022
Q2
$487K Buy
3,683
+455
+14% +$59.7K 0.09% 94
2022
Q1
$428K Buy
3,228
+453
+16% +$54.3K 0.08% 107
2021
Q4
$323K Sell
2,775
-750
-21% -$88.2K 0.06% 129
2021
Q3
$423K Buy
3,525
+673
+24% +$78.3K 0.1% 99
2021
Q2
$342K Buy
2,852
+590
+26% +$64.7K 0.08% 116
2021
Q1
$225K Buy
2,262
+140
+7% +$14.1K 0.07% 144
2020
Q4
$212K Buy
2,122
+169
+9% +$17.9K 0.07% 141
2020
Q3
$214K Buy
+1,953
New +$217K 0.09% 125

Other funds holding AZN

PDS Planning's AZN Position: Q2 2026 in Review

PDS Planning reduced its AstraZeneca (AZN) stake by 0.63% in Q2 2026, selling an estimated $8.28K and leaving 6,926 shares worth $1.31M. The position accounts for 0.08% of the portfolio, ranked #126.

PDS Planning first reported a position in AZN in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.37M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • PDS Planning held 6,926 shares of AstraZeneca worth $1.31M as of Q2 2026.
  • PDS Planning sold 44 AstraZeneca shares in Q2 2026, an estimated $8.28K.
  • AstraZeneca made up 0.08% of PDS Planning's portfolio in Q2 2026, its #126 holding.
  • PDS Planning first reported a position in AstraZeneca in Q3 2020 and has held it in 24 quarters since.
  • PDS Planning's AstraZeneca position peaked at $1.37M in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on PDS Planning's 13F filing for Q2 2026, filed 5 Aug 2026.